Plant-produced SARS-CoV-2 antibody engineered towards enhanced potency and in vivo efficacy.

ABSTRACT: Prevention of severe COVID-19 disease by SARS-CoV-2 in high-risk patients, such as immuno-compromised individuals, can be achieved by administration of antibody prophylaxis, but producing antibodies can be costly. Plant expression platforms allow substantial lower production costs compared to traditional bio-manufacturing platforms depending on mammalian cells in bioreactors. In this study, we describe the expression, production and purification of the originally human COVA2-15 antibody in plants. Our plant-produced mAbs demonstrated comparable neutralizing activity with COVA2-15 produced in mammalian cells. Furthermore, they exhibited similar capacity to prevent SARS-CoV-2 infection in a hamster model. To further enhance these biosimilars, we performed three glyco- and protein engineering

SUBMITTER: de Taeye SW 

PROVIDER: S-EPMC11672753 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature